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Abstract
Background: Approximately 20% of oocytes are classified as immature and discarded following intracytoplasmic sperm
injection (ICSI) procedures. These oocytes are obtained from gonadotropin-stimulated patients, and are routinely removed
from the cumulus cells which normally would mature the oocytes. Given the ready access to these human oocytes, they
represent a potential resource for both clinical and basic science application. However culture conditions for the maturation
of cumulus-free oocytes have not been optimized. We aimed to improve maturation conditions for cumulus-free oocytes via
culture with ovarian paracrine/autocrine factors identified by single cell analysis.
Methodology/Principal Finding: Immature human oocytes were matured in vitro via supplementation with ovarian
paracrine/autocrine factors that were selected based on expression of ligands in the cumulus cells and their corresponding
receptors in oocytes. Matured oocytes were artificially activated to assess developmental competence. Gene expression
profiles of parthenotes were compared to IVF/ICSI embryos at morula and blastocyst stages. Following incubation in
medium supplemented with ovarian factors (BDNF, IGF-I, estradiol, GDNF, FGF2 and leptin), a greater percentage of oocytes
demonstrated nuclear maturation and subsequently, underwent parthenogenesis relative to control. Similarly, cytoplasmic
maturation was also improved as indicated by development to blastocyst stage. Parthenogenic blastocysts exhibited mRNA
expression profiles similar to those of blastocysts obtained after IVF/ICSI with the exception for MKLP2 and PEG1.
Conclusions/Significance: Human cumulus-free oocytes from hormone-stimulated cycles are capable of developing to
blastocysts when cultured with ovarian factor supplementation. Our improved IVM culture conditions may be used for
obtaining mature oocytes for clinical purposes and/or for derivation of embryonic stem cells following parthenogenesis or
nuclear transfer.
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Introduction
Approximately 20% of oocytes routinely retrieved following
hormone stimulation are classified as immature (termed germinal
vesicle (GV) or metaphase I (MI) stage); these oocytes are
discarded due to their reduced potential for embryo development
under current culture conditions [1]. However, this cohort of
oocytes is useful for studies aimed at elucidating the mechanisms of
in vitro maturation of human oocytes and might ultimately
contribute to the pool of embryos available for embryo transfer
[2]. In addition, cumulus-free human oocytes may provide a
platform for derivation of patient-specific embryonic stem cells
(hESCs) including parthenogenic embryonic stem cells (pESCs) or
somatic cell nuclear transfer-embryonic stem cells (SCNT-ESCs).
Since the first report of in vitro human oocyte maturation in 1969
[3], several reports have documented blastocyst (BL) development
or live birth achieved from oocytes matured in vitro [1,4,5].
However, nuclear and cytoplasmic maturation of cumulus-free
oocytes remains suboptimal at best [2,6,7]. Moreover, ability of
this cohort of oocytes to support the development of parthenogenic
or nuclear transfer embryos to blastocyst stage has not been
assessed.
The cumulus cells that surround oocytes within follicles
modulate nuclear and cytoplasmic maturation by both physical
cell-cell contact and the combined actions of paracrine factors [8].
However, during the process of intracytoplasmic sperm injection
(ICSI), cumulus cells must be removed from oocytes. When these
cumulus-free oocytes are directly exposed to commercially-
available maturation media, they subsequently exhibit delayed
oocyte maturation and abnormal embryo development [1,2]. In
the majority of studies of in vitro maturation (IVM), follicle
stimulating hormone (FSH), luteinizing hormone (LH), estradiol
and epidermal growth factor (EGF) are used as supplements.
However, whether human oocytes express the receptors for FSH
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oocyte maturation through the EGF receptor (EGFR), which is
expressed by cumulus cells rather than the oocyte [11]. As outlined
below, we used a microfluidic quantitative PCR (qPCR) system to
elucidate the gene expression profiles of individual human oocytes
and small numbers of cumulus cells using a combination of a large
number of samples and targets [12], and then extended our studies
via the use of parthenogenesis, in conjunction with gene expression
profiling, as a functional assay of cytoplasmic maturation of
oocytes.
Parthenogenesis in vitro is accomplished by artificial activation
without sperm contribution [2]. In vivo, mammalian parthenotes
are not able to develop to term due to aberrant, uniparental
imprinting and consequent developmental abnormalities [13,14].
Parthenogenesis, which can be induced in vitro by various electric,
mechanical or chemical stimulations, is a valuable functional assay
of oocyte developmental competence [15]. Also, pESC lines, that
carry isogenic genome information from the oocyte donors, can be
derived and may represent a potential alternative source of stem
cells for basic scientific studies as well as novel therapeutic
application. Although human pESCs have been derived from
different oocyte sources such as donated mature or cryopreserved
oocytes [16,17], in vitro-matured oocytes present a potentially-
abundant source for production of parthenogenic blastocysts.
Here, we report improved methods for in vitro maturation of
cumulus-free human oocytes by supplemented culture media with
ovarian paracrine/autocrine growth factors that were selected on
the basis of gene expression profiles of single human oocytes and
associated cumulus cells. Then we tested functionality of oocytes
matured in vitro by assessing the ability to develop to the blastocyst
stage, and by comparing the gene expression profiles of
parthenogenic embryos and those obtained from IVF/ICSI.
Results
Expression of genes for paracrine/autocrine ligands and
their cognate receptors in oocytes and cumulus cells
In order to improve culture conditions for maturation of
cumulus-free oocytes in vitro, we began by assaying the expression
of 15 growth factors (BDNF, IGF-I, estradiol, GDNF, leptin,
FGF1, FGF2, GM-CSF, EGF, TGF-a, TGF-b1;2;3, and ET-1;2)
and 27 of their cognate receptors that have been shown to regulate
oocyte maturation. Selection was based on published literature
deposited in two online databases (http://ovary.stanford.edu/ and
http://receptome.stanford.edu/HPMR/) [18,19]. Four different
stages of oocytes, striped of their zona pellucida (ZP), were assayed:
1) GV (germinal vesicle), 2) MI (metaphase I), 3) MII
(spontaneously matured metaphase II before IVM) and 4) IVM-
MII (in vitro matured metaphase II). We confirmed the purity of
ZP-free oocytes and cumulus cell samples based on the exclusive
expression of known oocyte-specific and cumulus cell-specific
genes. As expected, expression of the genes NLRP5, GDF9 and ZP1
was limited to oocytes, while expression of the genes CD14, FSHR
and LHR, was limited to cumulus cells (Figure 1).
We examined expression of a set of candidate receptors and
ligands in oocytes and cumulus cells, respectively (Figure 2A, 2B
and S1). Among the growth factors, expression of mRNA of genes
that encode for GDNF, FGF2, GM-CSF and TGF-b1 was
significantly higher in cumulus cells than in oocytes. Conversely,
the majority of receptors were detected at the mRNA level in
oocytes with the exception for FGFR3, CSF2Rb, EGFR and TGF-
bR2. Among the receptors, expression of mRNA of genes that
encode for NTRK2, NGFRAP1, ESR1 and EDNRA was higher
in cumulus cells, while oocytes had significantly higher expression
of mRNA of genes that encode for IGF1R, ESR2 and TGF-bR3.
Figure 1. Expressions of oocyte-specific or cumulus cell-specific genes. Values are the means of different stages of oocytes including GV
(N=10), MI (N=8), MII (N=9), IVM-MII (N=10) and cumulus cells (N=5). Error bars represent standard deviation (SD). CNRQ: calculated normalized
relative quantity. *: Not detected in all samples.
a,b or
c,d: Values were significantly different (P,0.05).
doi:10.1371/journal.pone.0010979.g001
Immature Human Oocytes
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e10979Figure 2. Expressions of ovarian paracrine/autocrine factors and their cognate receptors selected for supplementation in in vitro
maturation media. (A) Ovarian paracrine/autocrine ligands, (B) their cognate receptors, and (C) schematic representation of gene expressions.
Values are the means of different stages of oocytes including GV (N=10), MI (N=8), MII (N=9), IVM-MII (N=10) and cumulus cells (N=5). Error bars
represent standard deviation (SD). CNRQ=calculated normalized relative quantity. *: No detected in all samples.
a,b or
c,d: Values were significantly
different (P,0.05), underline: low expression level, #: adopted from Hillier et al. [46].
doi:10.1371/journal.pone.0010979.g002
Immature Human Oocytes
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cumulus cells (CSF2Rb and EGFR) or oocytes (GDNFR, FGF2R).
We observed that even though the expression of the ligand, BDNF
was low in cumulus cells compared to oocytes, its receptors,
NTRK2 and NGFRAP1 were expressed in both oocytes and
cumulus cells. In particular, NGFRAP1 was expressed more than
350 fold higher in cumulus cells than in oocytes. We also noted
that mRNA of only two genes (IGF-I and leptin) was not expressed
at detectable levels in either compartment, oocytes or cumulus
cells. However, mRNA corresponding to their receptors, IGF1R
and LEPR, was expressed in both oocytes and cumulus cells.
Six ovarian factors (BDNF, IGF-I, estradiol, GDNF, leptin and
FGF2) were further studied based upon the expression of their
receptors in oocytes and cumulus cells described above, as well as
the availability of growth factor concentration information from
previous animal model studies [1,20,21,22,23]. We derived a
protocol for paracrine/autocrine supplementation for in vitro
maturation of cumulus-free oocytes that includes supplementation
with BDNF, IGF-I, GDNF, leptin, FGF2 and estradiol as shown in
Figure 2C.
Effect of ovarian paracrine/autocrine supplement on
oocyte nuclear maturation
To test whether culture supplementation to promote nuclear
maturation, we assessed the polar body extrusion after culture of
immature GV and MI oocytes in three different maturation
conditions: 1) Commercial human oocyte maturation medium
(Sage), 2) IVM-medium, and 3) IVM-medium supplemented with
selected ovarian factors as described above and in Materials and
Methods. As shown in Table 1, as expected, nuclear maturation of
GV oocytes was less efficient than MI oocytes. Among the GV
oocytes, 50–68% of oocytes extruded a first polar body within 48 h
in the three different media. Significant differences were not
observed with the GV oocyte nuclear maturation between any of
the three media. In contrast, nuclear maturation of MI oocytes
was much more efficient with values ranging from 75 to 94% in
the three different media. The supplementation of MI oocytes in
IVM-medium with ovarian factors demonstrated significantly
higher rates of extruding a first polar body (94%) relative to media
without supplementation (75%) (Table 1).
Functional analysis of ovarian paracrine/autocrine
supplement via assessment of parthenote development
We used parthenogenic development as a functional assay of
cytoplasmic maturation. Following chemical activation of oocytes
matured in vitro, we monitored cleavage and development of the
parthenotes daily. We observed that following activation, culture
in both Sage and IVM-supplementation media demonstrated
significantly higher cleavage rates (87.2% and 82.3%, respectively)
compared to IVM-medium alone (55.6%). Most notably, however,
parthenogenic blastocysts were only produced from embryos
cultured with supplementation and not with Sage or IVM-medium
alone (Table 2 and Figure S2).
Gene expression profiling of human parthenotes
A total of 67 genes, from 10 functional categories related to
embryo development were selected for analysis of parthenogenic
and IVF/ICSI embryos. The categories included RNA pathway (5
genes), zygotic activation (4 genes), histone modification (10 genes),
DNA methylation (6 genes), imprinting (6 genes), miRNA
biogenesis (4 genes), pluripotency (3 genes), growth factor
receptors (20 genes), maternal factors (4 genes) and cytokinesis (5
genes). These genes were selected for analysis of parthenogenic
and IVF/ICSI embryos at the morula and blastocyst stage based
primarily on published reports from non-human model systems
(Figure 3, 4A, 4B and Table S2). In our data analysis, we observed
97% similarity in mRNA expression between parthenotes and
IVF/ICSI embryos at the blastocyst stage (Figure 3 and 4B), with
reduced similarity at the morula stage (83.6%, Figure 3 and 4A).
More specifically, only the mRNAs of genes that encode for
MKLP2 and PEG1 were expressed at lower levels in partheno-
genic blastocysts in comparison to IVF/ICSI blastocysts
(Figure 4B). Genes that encode for DNMT3A and MEG3 were
expressed only in parthenotes but not in IVF/ICSI at the morula
stage. Parthenogenic morula also had significantly higher
expression levels of the mRNAs for DNMT3B, PEG1, DICER,
NLRP5, NTRK2, NTRK3, CPEB1, CCNA1 and EIF1AX
(Figure 4A).
Discussion
In this study, we first used a microfluidic quantitative PCR
system to elucidate the gene expression profiles of single human
oocytes and small groups of cumulus cells and subsequently
improved upon in vitro maturation of cumulus-free oocytes to
obtain parthenogenic blastocysts. We also observed that parthe-
notes from in vitro matured oocytes have similar mRNA expression
levels of the majority of studied genes compared to IVF/ICSI
embryos at the blastocyst stage.
Analysis of gene expression in single human oocytes and small
groups of cumulus cells revealed notable similarities and
differences from previous reports including human and model
organisms. FSH, LH, estradiol and EGF are commonly used to
promote maturation of cumulus-enclosed oocytes. According to
the mRNA expression analysis in our study, there is negligible
expression of the receptors for FSH, LH and EGF in human
oocytes. This is consistent with a recent animal study [9] but
contradictory to a previous report showing FSHR and LHR
mRNA expression in mouse oocytes and pre-implantation
embryos [10]. Furthermore, parthenote development in Sage
medium with hormone supplementation did not improve late
stage (further than 8-cells) embryo development compared to
Table 1. Nuclear maturation of cumulus-free human oocytes
in vitro from hormone-stimulated cycle.
Oocytes Culture media No. of oocytes Nuclear maturation rate (%)
24 h 48 h
GV Sage 45 22 (48.9) 31 (68.9)
IVM-medium 46 19 (41.3) 23 (50.0)
Supplement 98 45 (45.9) 53 (54.1)
MI Sage 42 37 (88.1) 37 (88.1)
IVM-medium 29 21 (72.4)
a 22 (75.9)
a
Supplement 51 48 (94.1)
b 48 (94.1)
b
Sage: commercial IVM medium supplemented with 10% SPS, FSH, hCG and
estradiol.
IVM-medium: IVM-medium supplemented with 10% SPS.
Supplement: IVM-medium supplemented with 10% SPS, BDNF, estradiol, IGF-I,
GDNF, FGF2, leptin.
GV: germinal vesicle stage.
MI: metaphase I stage.
Nuclear maturation: the presence of a first polar body.
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ment data suggest that FSH and LH may not affect oocyte nuclear
and cytoplasmic maturation directly. In contrast, both ESR1 and
ESR2, the receptors for estradiol, were detected in oocytes as well
as cumulus cells in our study, suggesting a role for estradiol in
oocyte maturation [24]. Therefore, the higher cleavage rate in
Sage medium compared to IVM-medium alone is most likely due
to the estradiol supplementation in Sage medium.
Both animal and human studies have demonstrated the
important roles of neurotrophins (BDNF, NTF3 and NTF4) in
oocyte maturation mediated by their receptors (NTRK1–3 and
NGFRAP1) [20,25]. We observed expression of BDNF mRNA
and its receptors (NTRK2 and NGFRAP1) in both oocytes and
cumulus cells. The higher expression of NGFRAP1 in cumulus cells
suggests that BDNF may have a role in cumulus cell functions. It is
important to note that the probe for NTRK2 in our study detected
both the full length as well as the truncated forms of NTRK2.W e
suspect that the NTRK2 mRNA expression observed in the present
study is the truncated form, since the full length form was not
detected in either human oocytes or cumulus cells previously [26].
Interestingly, NGFRAP1 was detected in oocytes in our study but
not in the previous study [26]. This may reflect the greater
sensitivity of our microfluidic qPCR system over other traditional
qPCR systems. Also, the previous study was conducted with
cumulus-oocyte-complexes from small antral follicles without
hormone stimulation, which may dramatically change the mRNA
expression profiles compared to those undergoing hormone
stimulation.
Expression of the mRNA encode for Glial cell line-Derived
Neurotrophic Factor (GDNF) was detected in cumulus cells as
shown previously [22] as well as oocytes in our study. GDNF is
secreted by cumulus, granulosa, and theca cells as an ovarian
factor stimulated by the preovulatory LH surge [22], and induces
oocyte maturation and embryo developmental competence [27]
by GDNFR and rearranged during transformation (RET). Based
on the findings that GDNFR is only expressed in oocytes, and a
low level of RET expression was detected in both oocytes and
cumulus cells, our data suggest that GDNF might increase oocyte
maturation by both a paracrine and autocrine manner in humans.
At the mRNA level, FGF2 was highly expressed in cumulus
cells, while its receptor FGF2R was highly expressed in oocytes in
our study. FGF2 and its receptors have been shown to be
expressed at the protein level by both oocytes and granulosa cells
up to secondary follicles [28], but the expression patterns in antral
follicles have not been studied to date. Based on our gene
expression data, FGF2 could affect oocyte maturation in a
paracrine manner via the cumulus cells. This notion is supported
by a previous study showing a higher concentration of FGF2 in
follicular fluid compared to serum [29] and suggests that FGF2
production from the ovary has pivotal functions during follicle
development and oocyte maturation.
Two parthenogenic blastocysts were produced from in vitro
matured GV oocytes from hormone-stimulated cycles in our study.
This is a proof of principle to demonstrate that immature oocytes
are able to achieve the developmental competence with selected
ovarian factors in vitro. In spite of ovarian factor supplementation,
nuclear maturation of GV oocytes was not improved compared to
MI stage oocytes. It may be due to the fact that the majority GV
oocytes might be collected from pre-antral follicles which are not
able to resume meiosis [30]. However, detailed protein expression
of individual ovarian factors and their receptors in oocytes need to
be further studied in order to elucidate the factors that may affect
oocytes in specific maturation stages.
Once we had optimized the in vitro maturation of oocytes, we
were able to obtain parthenogenic morulas and blastocysts in
culture. It is noteworthy that this is the first study to show the gene
expression profiles of human parthenogenic embryos at any stage.
Overall, parthenotes have similar mRNA expression levels as
IVF/ICSI embryos at the blastocyst stages (Figure 3 and 4B). The
altered expression patterns of Cyclin A1 (CCNA1) in parthenotes
changed from high (in morula) to low (in BLs) compared to IVF/
ICSI embryos, which may due to it inefficient zygote genomic
activation [31]. The altered expression of CCNA1 is similar to the
expression of EIF1AX, another marker for zygotic genomic
activation in our study as well as in a previous animal study [32].
However, we cannot suspect any abnormal effect on parthenotes
due to the aberrant expression of CCNA1 since the protein is not
expressed at the blastocyst stage [33], and its cell cycle regulation
role is limited in meiotic cells [34]. Higher expression of
cytoplasmic polyadenylation element-binding protein 1 (CPEB1)
in parthenotes compared to normal embryos may increase cell
cycle arrest and cellular senescence by inducing p53 translation
[35]. This may cause lower cell number and higher apoptosis in
parthenotes compared to normal embryos [14].
The mRNA expression pattern of growth factor receptors in
parthenotes were different compared to normal embryos,
suggesting that growth factors supplemented in oocyte/embryo
culture media may alter the expression of their receptors [36].
Interestingly, BDNF improves pregnancy rates by increasing
trophoblast cell growth and survival via its receptor NTRK2
expressed by the trophectoderm of blastocysts [37]. The effect of
higher expression of NTRK2 and NTRK3 mRNA in parthenotes
need to be further studied.
Aberrant imprinting is the major cause of embryo lethality of
parthenogenic embryos. In our study, morula stage parthenotes
exhibited high expression levels of MEG3 and PEG1. Maternally
Table 2. Embryo development after parthenogenetic activation of human oocytes matured in vitro.





Sage 66 47 (71.1) 41 (87.2)
b 4 (9.8) -
IVM-medium 44 36 (81.8) 20 (55.6)
a 3 (15.0) -
Supplement 77 62 (80.5) 51 (82.3)
b 7 (13.7) 3 (5.9)
Sage: commercial IVM medium supplemented with FSH, hCG and estradiol.
IVM-medium: IVM-medium supplemented with 10% SPS.
Supplement: IVM-medium supplemented with BDNF, estradiol, IGF-I, GDNF, FGF2, leptin.
*Percentage from activated oocytes.
**Percentage from cleaved embryos.
a,bWithin columns, values with different superscripts were significantly different (P,0.05).
doi:10.1371/journal.pone.0010979.t002
Immature Human Oocytes
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PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e10979expressed MEG3 is regulated by a intergenic differentially
methylated region in human gametes and embryos [38]. A
possible explanation for this finding is that residual mRNA
expression from oocytes was still present in morula stage
parthenotes and/or chemical activation induced the aberrant
expression of certain genes in parthenotes. Paternally expressed
PEG1 exhibited significantly higher levels in parthenotes at the
morula stage and dramatically decreased at the blastocyst stage.
The high expression levels of two genes (DNMT3A and DNMT3B)
related to DNA methylation in our study is also consistent with a
mouse study showing the elevated methylation in parthenotes
compared to IVF/ICSI embryos [39]. Analogous to CCNA1 and
EIF1AX discussed above, the higher expression of de novo
methyltransferase, DNMT3B, in parthenotes may be due to the
altered zygotic activation since DNMT3B expression has been
shown to be originated from embryo [40]. The regulation of
epigenetic modifications in human pre-implantation embryos
needs to be explored in further depth in order to understand the
underlying molecular mechanisms behind early human develop-
ment as well as the low efficiency of parthenogenesis and SCNT.
In our study, cleaved day 3 parthenotes were used to establish
pESCs from single blastomeres using derivation methods as
previously described [41]. Of the blastomeres isolated, approxi-
mately 21% (8 out of 38) divided once, but no blastocele could be
detected in arrested parthenotes. Only blastomeres from non-
arrested 8-cell stage parthenote formed blastoceles and prolifer-
ated (data not shown). From the 8 blastomeres isolated from an 8-
cell parthenote, 3 blastomeres divided, which suggested that those
3 blastomeres are the most viable from the original 8-cell
parthenote. This interpretation is supported by a previous study
showing that the blastomeres from arrested human embryos still
divided in vitro when isolated from the original embryos [42]. The
results indicate the potential for individual blastomere growth and
development from parthenotes obtained from in vitro maturation in
spite of the fact that we did not derive a pESC line at this time. It
would be useful to compare the potential of day 2 parthenotes
which are more abundant since an ESC line was recently derived
from 4-cell blastomeres [43].
In conclusion, cumulus-free human oocytes from hormone-
stimulated cycles can be matured in vitro with the supplementation
of ovarian paracrine/autocrine factors to achieve embryo
developmental competence to blastocysts. Also, parthenogenic
blatocysts from IVM oocytes exhibit similar gene expression
profiles of selected genes compared to IVF/ICSI. Parthenogenesis
is one of key steps towards successful human SCNT. Our
improved IVM culture conditions may be used for supplying




Oocytes, cumulus cells and frozen embryos were collected from
Stanford Fertility and Reproductive Medicine Center after
approval by the Stanford Institutional Review Board (IRB); all
samples were obtained with written informed consent from all
participants involved in the study. Patients who had fewer than
50% mature oocytes were excluded from the oocyte donation.
Protocols for controlled ovarian hyperstimulation and oocyte
retrieval were as described previously [7]. Cumulus-free immature
oocytes from consenting ICSI patients were obtained 6–8 h after
oocyte retrieval and transferred to the research laboratory.
Gene expression profiling of oocytes and cumulus cells
For analyses of gene expression in oocytes and cumulus cells, the
following samples were collected; 10 GV (germinal vesicle), 8 MI
(metaphase I), 9 MII (spontaneously matured metaphase II before
IVM), 10 IVM-MII (in vitro matured metaphase II) oocytes, and 5
cumulus aggregates containing 5–10 cells of corona radiata.
Oocytes and cumulus cells were collected from 21 patients
undergoing ICSI treatment. Two GV oocytes were collected from
2 PCOS (polycystic ovarian syndrome) patients. Removal of the
zona pellucid (ZP) was accomplished by treatment with acidic
tyrode (Millipore Co., Billerica, MA), and samples were stored at
280uC until use. The BioMark Dynamic Array microfluidic
qPCR system (Fluidigm Corporation, San Francisco, CA) was
used for gene expressions analysis of oocytes and cumulus cells.
Individual oocytes or small groups of cumulus cells were pre-
amplified according to the manufacturer’s protocol (Fluidigm Co.)
using 206 Taqman gene expression assays (Applied Biosystems,
Foster City, CA) as listed in Table S1. Reaction mix contained
2.5 ml2 6 Universal Master Mix (Applied Biosystems), 0.25 ml
Sample Loading Buffer (Fluidigm Co.), and 2.25 ml pre-amplified
cDNA for loading into the sample inlets of the 48 by 48 Dynamic
Array (DA) (Fluidigm Co.). For probes, the reaction mix contained
2.5 ml2 0 6 Taqman gene expression assay and 2.5 ml Assay
Loading Buffer (Fluidigm Co.) for loading into the assay inlets on
the DA. Each sample was assayed in duplicate, and CNRQ
(calculated normalized relative quantity) values were calculated by
classic delta-delta-Ct method and normalized to the multiple
housekeeping genes, large, P0 (RPLPO) and glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) as a control using the
qBasePlus 1.3 analysis software (http://www.biogazelle.com)
[44].
In vitro maturation
Cumulus-free human oocytes from hormone stimulated ICSI
patients were matured in three different conditions: 1) Sage
(commercial oocyte maturation medium, Coopersurgical/Sage,
Trumbull, CT) supplemented with 10% serum protein substitute
(SPS), 0.075 IU/ml recombinant FSH (rFSH, Serono Laborato-
ries, Randolph, MA), 0.025 mg/ml recombinant human chorionic
gonadotrophin (rhCG, Serono Laboratories), 1 mg/ml estradiol
(Sigma-Aldrich, St. Louis, MO) based on previous studies [1,6], 2)
IVM-medium based on previous report with minor modification
of addition of 0.5 mg/l human transferrin supplemented with 10%
SPS [1,45], and 3) IVM-medium supplemented with 10% SPS
and ovarian paracrine/autocrine factors [3 ng/ml of BDNF
(PeptroTech Inc., Rocky Hill, NJ), 100 ng/ml of IGF-I (Sigma-
Aldrich), 1 mg/ml of estradiol, 30 ng/ml of GDNF (R&D System
Inc., Minneapolis, MN), 10 ng/ml of leptin (PeptroTech Inc.), and
0.5 ng/ml of FGF2 (R&D System Inc.)] based on results described
above on expression of receptors in oocytes. A total of 189 GV and
122 MI cumulus-free oocytes from more than 90 patients were
matured at 37uCi n6 %C O 2,5 %O 2 and 89% N2. Nuclear
maturation was characterized by the presence of a first polar body
(metaphase II) at 24 and 48 h after IVM, and cytoplasmic
maturation was determined by extent of early embryo develop-
ment following chemical activation.
Figure 3. Treeview display of cluster analysis of gene expression of all morulas and blastocysts from parthenogenesis and IVF/ICSI.
PM=parthenogenic morula, PBL=parthenogenic blastocyst.
doi:10.1371/journal.pone.0010979.g003
Immature Human Oocytes
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parthenogenesis and embryo culture in vitro
Following in vitro maturation, oocytes at metaphase II with the
presence of a first polar body were activated using 10 mMc a l c i u m
ionophore A23187 (Sigma-Aldrich) for 5 min followed by 2 mM
DMAP(Sigma-Aldrich)for4 hat37uCi n6 %CO 2,5%O 2and 89%
N2. Activated oocytes were subsequently cultured in biphasic culture
medium, Quinn’s Cleavage and Blastocyst media (Coopersurgical)
supplemented with 10% SPS and growth factors [10 ng/ml of
BDNF, 40 ng/ml of IGF-I, 5 ng/ml of EGF (R&D System Inc.),
2 ng/ml of GM-CSF (R&D System Inc.), 0.5 ng/ml FGF2, and
10 ng/ml of GDNF] at 37uCi n6 %C O 2,5 %O 2 and 89% N2.
Embryo development was monitored via microscopy daily for 7 days.
Gene expression profiling of parthenotes and IVF/ICSI
embryos
For analyses of gene expression in embryos, cryopreserved day 3
embryos and day 6 blastocysts from 10 IVF/ICSI patients were
thawed via an embryo thawing kit (Cooper Surgical) or a
blastocyst thawing kit (Cooper Surgical), respectively, according
to manufacturer’s protocol. Eight morulas and seven blastocysts
were harvested after culturing in Quinn’s Blastocyst media
supplemented with 10% SPS at 37uCi n6 %C O 2,5 %O 2 and
89% N2. Two parthenogenic morulas and three parthenogenic
blastocysts were also collected on day 5 and 6 of in vitro culture,
respectively. The Taqman gene expression assays were as listed
(Table S2). CNRQ values were calculated by classic delta-delta-Ct
method and normalized to the multiple housekeeping genes,
cadherin-associated protein, beta 1(CTNNB1) and GAPDH using
the qBasePlus 1.3 analysis software. CNRQ values were converted
into a log2 value, and imported into the clustering program,
Cluster 3.0, and visualized by TreeView software (http://rana.lbl.
gov).
Statistical analysis
Oocyte maturation and embryo development data were entered
into a two-by-two contingency table, and Fisher’s exact test was
used to generate P-values in Prism version 5.02 for windows
(GraphPad Software, Inc.). Gene expression data (CNRQ) of
oocytes and cumulus cells were analyzed by one-way ANOVA
with Bonferroni post test in Prism version 5.02. Gene expression
data of embryos were analyzed by one-way ANOVA in JMPH
software (SAS Institute, Cary, NC). Significant differences between
experimental groups were noted when the comparison-wise P-
value was less than 0.05.
Supporting Information
Figure S1 Expression data for ovarian paracrine/autocrine
factors and their cognate receptors that were not subsequently
used for supplementation in in vitro. (A) Paracrine/autocrine
ligands, and (B) their cognate receptors. Values are the means of
different stages of oocytes including GV (N=10), MI (N=8), MII
(N=9), IVM-MII (N=10) and cumulus cells (N=5). Error bars
represent standard deviation (SD). CNRQ: calculated normalized
relative quantity. *: Not detected in all samples. a,b or c,d: Values
were significantly different (P,0.05).
Found at: doi:10.1371/journal.pone.0010979.s001 (0.94 MB TIF)
Figure S2 Development of parthenogenic embryos. Embryos on
day 1 (A) and day 3 (B,C); blastocysts on day 6 (D) and day 7 (E).
Cells were stained with Hoechst 33342 (F). The images were taken
either under 3006(A, B, E, F) or 2006(C, D) magnification.
Found at: doi:10.1371/journal.pone.0010979.s002 (4.97 MB TIF)
Table S1 Taqman probe assay numbers for genes tested in
oocytes and cumulus cells.
Found at: doi:10.1371/journal.pone.0010979.s003 (0.06 MB
DOC)
Table S2 Taqman probe assay numbers for genes tested in
embryos.
Found at: doi:10.1371/journal.pone.0010979.s004 (0.09 MB
DOC)
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